Evidence map›Paper›PMID 32405080›Full record

ArticleClinica chimica acta; international journal of clinical chemistry2020

Decreased T cell populations contribute to the increased severity of COVID-19.

Rui Liu, Ying Wang, Jie Li, Huan Han, Zunen Xia, Fang Liu, Kailang Wu, Lan Yang, Xinghui Liu, Chengliang Zhu

Abstract read
In one paragraph

Article in Clinica chimica acta; international journal of clinical chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Lymphocyte Subset Counts in COVID-19 Patients: A Meta-Analysis.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2020
    Pooled it
  8. Trial
  9. Trial
  10. Upregulation of CCR4 in activated CD8European journal of immunology · 2021
    Trial
  11. Article
  12. Review
  13. Article
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Rui LiuDepartment of Clinical Laboratory, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, PR China.
Ying WangShanghai Health Commission Key Lab of Artificial Intelligence (AI)-Based Management of Inflammation and Chronic Diseases, Sino-French Cooperative Central Lab, Shanghai Pudong Gongli Hospital, Secondary Military Medical University, Shanghai 200135, PR China.
Jie LiPostgraduate training base in Shanghai Gongli Hospital, Ningxia medical university, Pudong New Area, Shanghai200135, PR China.
Huan HanDepartment of Clinical Laboratory, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, PR China.
Zunen XiaDepartment of Clinical Laboratory, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, PR China.
Fang LiuState Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, Hubei 430072, PR China; Wuhan Institute of Biotechnology, Wuhan, Hubei 430075, PR China.
Kailang WuState Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, Hubei 430072, PR China.
Lan YangDepartment of Clinical Laboratory, Shanghai Gongli Hospital, the Second Military Medical University, Pudong New Area, Shanghai200135, PR China.
Xinghui LiuDepartment of Clinical Laboratory, Shanghai Gongli Hospital, the Second Military Medical University, Pudong New Area, Shanghai200135, PR China.
Chengliang ZhuDepartment of Clinical Laboratory, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, PR China. Electronic address: xinchengzhu@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe observe changes of the main lymphocyte subsets (CD16

methodsOne-hundred and fifty-four cases of COVID-19-infected patients were selected and divided into 3 groups (moderate group, severe group and critical group). The flow cytometry assay was performed to examine the numbers of lymphocyte subsets.

resultsCD3

conclusionsReduced CD3

Indexed as

AgedAged, 80 and overBetacoronavirusBiomarkersCardiovascular DiseasesCD3 ComplexCD4 AntigensCD8 AntigensCohort StudiesComorbidityCoronavirus InfectionsCOVID-19Diabetes MellitusFemaleGene ExpressionHumansBiomarkersCD3 ComplexCD4 AntigensCD8 AntigensCD3(+) T cellsCD4(+) T cellsCD8(+) T cellsCOVID-19Lymphocyte subsets

Identifiers

PMID32405080
PMCPMC7219428

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.